
Sign up to save your podcasts
Or


In this episode, Dr. JYP talks with Dr. Natalie Bath, M.D., a USA Health surgical oncologist, about a new groundbreaking cancer treatment for liver tumors called histotripsy. Histotripsy is a non-invasive technology that uses high-intensity sound waves to break up liver tumors without surgery, incisions or long recovery times. Patients go under general anesthesia, and the machine delivers sound waves to the cancer cells while the physician uses imaging to monitor the treatment. Most people go home the same day and recover quickly, needing only over-the-counter pain medication. This treatment works for different types of liver tumors, including those that have spread from other cancers, and it doesn't require people to stop blood thinners. Histotripsy is FDA-approved for liver tumors and offers hope for patients who might not have other options. This episode encourages patients to ask their doctors about all possible treatments and to keep learning more about their choices.
3 Key Listener Takeaways
Groundbreaking, Non-Invasive Liver Cancer Treatment
The episode introduces histotripsy, an exciting new technology that uses focused ultrasound waves from outside the body to destroy liver tumors in a non-invasive manner. This innovative approach preserves surrounding liver tissue and offers an option for patients who might not be candidates for surgery.
Eligibility and Patient Benefits
Histotripsy can be used to treat both primary liver cancer and metastatic cancers from other sites. It's especially promising for patients who are not surgical candidates or who are on medications like blood thinners that would otherwise complicate surgery. With minimal recovery — often just a same-day or next-day discharge — patients experience less downtime and can continue other therapies, such as chemotherapy or immunotherapy, without interruption.
Expansion of Treatment Options and Ongoing Research
The episode highlights how histotripsy adds to the arsenal of cancer care, offering hope and additional options, especially for those who previously had few. It is FDA-approved for liver tumors, with ongoing research exploring its use for kidney, prostate, and pancreatic cancers. Patients are encouraged to advocate for themselves, ask about new technologies, and seek out multimodal therapies that combine traditional and emerging treatments for the best possible outcomes.
Show Overview
00:45 Introduction to histotripsy, a groundbreaking, non-invasive treatment for liver tumors
01:26 Meet Dr. Natalie Bath
02:20 First adopter in Alabama
03:15 What patients can expect
04:55 Who is a candidate?
07:49 Benefits of non-invasive treatment
10:45 FDA approved for liver tumors
15:05 Potential uses for histotripsy
16:45 Where to learn more
In this episode, Dr. JYP talks with Dr. Natalie Bath, M.D., a USA Health surgical oncologist, about a new groundbreaking cancer treatment for liver tumors called histotripsy. Histotripsy is a non-invasive technology that uses high-intensity sound waves to break up liver tumors without surgery, incisions or long recovery times. Patients go under general anesthesia, and the machine delivers sound waves to the cancer cells while the physician uses imaging to monitor the treatment. Most people go home the same day and recover quickly, needing only over-the-counter pain medication. This treatment works for different types of liver tumors, including those that have spread from other cancers, and it doesn't require people to stop blood thinners. Histotripsy is FDA-approved for liver tumors and offers hope for patients who might not have other options. This episode encourages patients to ask their doctors about all possible treatments and to keep learning more about their choices.
3 Key Listener Takeaways
Groundbreaking, Non-Invasive Liver Cancer Treatment
The episode introduces histotripsy, an exciting new technology that uses focused ultrasound waves from outside the body to destroy liver tumors in a non-invasive manner. This innovative approach preserves surrounding liver tissue and offers an option for patients who might not be candidates for surgery.
Eligibility and Patient Benefits
Histotripsy can be used to treat both primary liver cancer and metastatic cancers from other sites. It's especially promising for patients who are not surgical candidates or who are on medications like blood thinners that would otherwise complicate surgery. With minimal recovery — often just a same-day or next-day discharge — patients experience less downtime and can continue other therapies, such as chemotherapy or immunotherapy, without interruption.
Expansion of Treatment Options and Ongoing Research
The episode highlights how histotripsy adds to the arsenal of cancer care, offering hope and additional options, especially for those who previously had few. It is FDA-approved for liver tumors, with ongoing research exploring its use for kidney, prostate, and pancreatic cancers. Patients are encouraged to advocate for themselves, ask about new technologies, and seek out multimodal therapies that combine traditional and emerging treatments for the best possible outcomes.
Show Overview
00:45 Introduction to histotripsy, a groundbreaking, non-invasive treatment for liver tumors
01:26 Meet Dr. Natalie Bath
02:20 First adopter in Alabama
03:15 What patients can expect
04:55 Who is a candidate?
07:49 Benefits of non-invasive treatment
10:45 FDA approved for liver tumors
15:05 Potential uses for histotripsy
16:45 Where to learn more
In this episode, Dr. JYP welcomes back Dr. Thomas Butler, a seasoned oncologist who specializes in supportive oncology. Dr. Butler shares his journey from humble beginnings and a fascination with science to a career in cancer care, emphasizing the importance of addressing both the physical and emotional needs of patients. He discusses the distinction between palliative and supportive care, advocating for an approach that supports patients throughout their cancer journey — not just at the end of life. Dr. Butler also offers personal insights from his own cancer diagnosis, reflecting on what he has learned regarding trust, honesty, spirituality, and quality of life. Listeners will hear practical advice for navigating cancer care and the value of a compassionate, team-based approach.
3 Key Listener Takeaways 1. Supportive care in oncology is essential and distinct from palliative care
Dr. Butler emphasizes the importance of supportive care, which focuses on alleviating the complications and side effects of cancer and its treatments. Unlike palliative care, which is often associated with end-of-life scenarios, supportive care is meant for patients at any stage of their cancer journey. Its goal is to address not just physical symptoms like pain and fatigue, but also emotional needs, ensuring patients don't have to suffer unnecessarily while undergoing treatment.
2. The value of listening and building trust between doctor and patient
A recurring theme throughout the conversation is the critical role trust and honest communication play in cancer care. Dr. Butler encourages patients to be open about their symptoms and concerns, highlighting that withholding information for fear of losing treatment options can hinder proper care. The relationship between oncologists and patients should be built on mutual respect and understanding, with doctors aiming to know the person and not just the disease.
3. Personal experience deepens provider empathy and influences care
Dr. Butler shares his journey from being an oncologist to becoming a cancer patient, which has profoundly impacted his outlook and practice. Experiencing cancer firsthand gave him a new perspective on the reality of side effects, the emotional burden of a diagnosis, and the importance of quality of life. This dual perspective has made him even more empathetic toward his patients and has reinforced his commitment to providing compassionate, holistic care where comfort and patient wishes are the top priorities.
In this episode, Dr. JYP welcomes back Dr. Thomas Butler, a seasoned oncologist who specializes in supportive oncology. Dr. Butler shares his journey from humble beginnings and a fascination with science to a career in cancer care, emphasizing the importance of addressing both the physical and emotional needs of patients. He discusses the distinction between palliative and supportive care, advocating for an approach that supports patients throughout their cancer journey — not just at the end of life. Dr. Butler also offers personal insights from his own cancer diagnosis, reflecting on what he has learned regarding trust, honesty, spirituality, and quality of life. Listeners will hear practical advice for navigating cancer care and the value of a compassionate, team-based approach.
3 Key Listener Takeaways 1. Supportive care in oncology is essential and distinct from palliative care
Dr. Butler emphasizes the importance of supportive care, which focuses on alleviating the complications and side effects of cancer and its treatments. Unlike palliative care, which is often associated with end-of-life scenarios, supportive care is meant for patients at any stage of their cancer journey. Its goal is to address not just physical symptoms like pain and fatigue, but also emotional needs, ensuring patients don't have to suffer unnecessarily while undergoing treatment.
2. The value of listening and building trust between doctor and patient
A recurring theme throughout the conversation is the critical role trust and honest communication play in cancer care. Dr. Butler encourages patients to be open about their symptoms and concerns, highlighting that withholding information for fear of losing treatment options can hinder proper care. The relationship between oncologists and patients should be built on mutual respect and understanding, with doctors aiming to know the person and not just the disease.
3. Personal experience deepens provider empathy and influences care
Dr. Butler shares his journey from being an oncologist to becoming a cancer patient, which has profoundly impacted his outlook and practice. Experiencing cancer firsthand gave him a new perspective on the reality of side effects, the emotional burden of a diagnosis, and the importance of quality of life. This dual perspective has made him even more empathetic toward his patients and has reinforced his commitment to providing compassionate, holistic care where comfort and patient wishes are the top priorities.
In this episode, Dr. JYP talks with Dr. J. Harrison Howard, a surgical oncologist who specializes in melanoma. Dr. Howard explains that not all skin cancers are the same, emphasizing that melanoma is more dangerous compared with basal cell and squamous cell carcinomas. He highlights the importance of detecting melanoma early, as it is the most dangerous form of skin cancer.
They discuss surgical and systemic treatment advancements, including the practice of sentinel lymph node biopsy and the game-changing benefits of immunotherapy. Dr. Howard says clinical trials are essential in improving treatment methods and increasing survival rates. He stresses the necessity of regular follow-ups for melanoma patients to catch any recurrence early. Lastly, Dr. Howard and Dr. JYP discuss skin cancer prevention, recommending sunscreen, protective clothing, and annual dermatologist visits to reduce the risk.
3 Key Takeaways 1. Diversity in skin cancer types: Not all skin cancers are created equal. Dr. Howard emphasizes the differences among various types of skin cancer, with a specific focus on melanoma. While basal cell carcinoma and squamous cell carcinoma are often treatable with surgery and have high cure rates, melanoma can quickly become life-threatening if not caught early. The depth of melanoma in the skin is critical, and it can spread and become fatal.
2. Advancements in melanoma treatment: There are exciting developments in both surgical and systemic treatments for melanoma. Dr. Howard talks about the trend toward less invasive surgery and the success of sentinel lymph node biopsy – developed by his late mentor, Dr. Donald Morton – as a significant advancement in minimizing side effects. Furthermore, systemic treatments such as immunotherapy are proving to be game-changing as they drastically improve survival rates for stage 4 melanoma.
3. Prevention and follow-up: The importance of prevention and regular monitoring is heavily emphasized. Sunscreen, protective clothing, and regular skin check-ups are crucial in reducing the risk of skin cancer. Dr. Howard also underscores that once someone has had melanoma, the risk of another melanoma greatly increases, necessitating lifelong vigilance and regular dermatologist visits to detect any cancers or pre-cancers early.
Show Overview
00:00 Basal cell and squamous cell carcinomas
05:08 Melanoma increases future risk tenfold
07:43 Development of sentinel lymph node biopsy
12:17 Redefining melanoma surgery
15:49 Clinical trials explained
17:43 To clinical trial participants: "You're a hero."
22:34 SPF-infused clothing for sun protection, and more
In this episode, Dr. JYP talks with Dr. J. Harrison Howard, a surgical oncologist who specializes in melanoma. Dr. Howard explains that not all skin cancers are the same, emphasizing that melanoma is more dangerous compared with basal cell and squamous cell carcinomas. He highlights the importance of detecting melanoma early, as it is the most dangerous form of skin cancer.
They discuss surgical and systemic treatment advancements, including the practice of sentinel lymph node biopsy and the game-changing benefits of immunotherapy. Dr. Howard says clinical trials are essential in improving treatment methods and increasing survival rates. He stresses the necessity of regular follow-ups for melanoma patients to catch any recurrence early. Lastly, Dr. Howard and Dr. JYP discuss skin cancer prevention, recommending sunscreen, protective clothing, and annual dermatologist visits to reduce the risk.
3 Key Takeaways 1. Diversity in skin cancer types: Not all skin cancers are created equal. Dr. Howard emphasizes the differences among various types of skin cancer, with a specific focus on melanoma. While basal cell carcinoma and squamous cell carcinoma are often treatable with surgery and have high cure rates, melanoma can quickly become life-threatening if not caught early. The depth of melanoma in the skin is critical, and it can spread and become fatal.
2. Advancements in melanoma treatment: There are exciting developments in both surgical and systemic treatments for melanoma. Dr. Howard talks about the trend toward less invasive surgery and the success of sentinel lymph node biopsy – developed by his late mentor, Dr. Donald Morton – as a significant advancement in minimizing side effects. Furthermore, systemic treatments such as immunotherapy are proving to be game-changing as they drastically improve survival rates for stage 4 melanoma.
3. Prevention and follow-up: The importance of prevention and regular monitoring is heavily emphasized. Sunscreen, protective clothing, and regular skin check-ups are crucial in reducing the risk of skin cancer. Dr. Howard also underscores that once someone has had melanoma, the risk of another melanoma greatly increases, necessitating lifelong vigilance and regular dermatologist visits to detect any cancers or pre-cancers early.
Show Overview
00:00 Basal cell and squamous cell carcinomas
05:08 Melanoma increases future risk tenfold
07:43 Development of sentinel lymph node biopsy
12:17 Redefining melanoma surgery
15:49 Clinical trials explained
17:43 To clinical trial participants: "You're a hero."
22:34 SPF-infused clothing for sun protection, and more
In this episode, Dr. JYP welcomes Margaret Wielbut, a trained art therapist who works with patients at the USA Health Mitchell Cancer Institute. Margaret delves into her personal journey, from discovering art therapy to implementing it in cancer care in Mobile, Alabama. She describes art therapy as a marriage between art and psychology, emphasizing its benefits for cancer patients in creating hope, reducing anxiety, and bringing purpose to the cancer journey.
She shares stories about how art can turn clinical spaces into environments of light and creativity. Sponsored by the Zoe Foundation, the MCI's art therapy program is free to patients. Margaret highlights the therapeutic power of creativity and her aspirations for expanding art therapy, including group projects and involving families. For those without access to art therapy, she recommends engaging in personal creative activities to enrich the healing journey.
3 Key Takeaways 1. Healing power of art therapy: Art therapy is described as a fusion between art and psychology, offering emotional healing and a creative outlet, which can be particularly beneficial for those on a cancer journey. Margaret highlights how art therapy has brought joy, reduced anxiety, and helped patients create meaning and enjoyment during their treatment.
2. Impact on cancer patients: The episode emphasizes the positive impact of art therapy on cancer patients, even those who may initially seem closed off or disinterested in the projects. Through creative sessions, patients can experience emotional breakthroughs, improve their mood and find a sense of community, as witnessed in the interactions facilitated by Margaret at the MCI.
3. Expanding art therapy in cancer care: Margaret discusses the value of expanding art therapy programs, including initiatives for children, and ideas to enhance patient engagement with group projects and art displays. The art created by patients not only serves as a personal therapeutic process but also contributes to a positive atmosphere within the clinical cancer space for all to enjoy.
In this episode, Dr. JYP welcomes Margaret Wielbut, a trained art therapist who works with patients at the USA Health Mitchell Cancer Institute. Margaret delves into her personal journey, from discovering art therapy to implementing it in cancer care in Mobile, Alabama. She describes art therapy as a marriage between art and psychology, emphasizing its benefits for cancer patients in creating hope, reducing anxiety, and bringing purpose to the cancer journey.
She shares stories about how art can turn clinical spaces into environments of light and creativity. Sponsored by the Zoe Foundation, the MCI's art therapy program is free to patients. Margaret highlights the therapeutic power of creativity and her aspirations for expanding art therapy, including group projects and involving families. For those without access to art therapy, she recommends engaging in personal creative activities to enrich the healing journey.
3 Key Takeaways 1. Healing power of art therapy: Art therapy is described as a fusion between art and psychology, offering emotional healing and a creative outlet, which can be particularly beneficial for those on a cancer journey. Margaret highlights how art therapy has brought joy, reduced anxiety, and helped patients create meaning and enjoyment during their treatment.
2. Impact on cancer patients: The episode emphasizes the positive impact of art therapy on cancer patients, even those who may initially seem closed off or disinterested in the projects. Through creative sessions, patients can experience emotional breakthroughs, improve their mood and find a sense of community, as witnessed in the interactions facilitated by Margaret at the MCI.
3. Expanding art therapy in cancer care: Margaret discusses the value of expanding art therapy programs, including initiatives for children, and ideas to enhance patient engagement with group projects and art displays. The art created by patients not only serves as a personal therapeutic process but also contributes to a positive atmosphere within the clinical cancer space for all to enjoy.
In this episode, Dr. JYP welcomes medical oncologist and hematologist Dr. Daisy Escobar to discuss her background and her expertise in cancer diagnosis and treatment. Dr. Escobar shares her journey to the Mitchell Cancer Institute and talks about her family. The conversation focuses on cell-free DNA technology, also known as liquid biopsy, which is used primarily for cancer surveillance and monitoring. Dr. Escobar explains the benefits and limitations of this technology, including how it compares with traditional biopsies and its potential in early cancer detection. The conversation also covers the emotional aspects of cancer surveillance and the importance of patient autonomy in treatment decisions. Dr. Escobar emphasizes the importance of continual research and advancements in cancer diagnostics to improve patient outcomes.
3 Key Listener Takeaways 1. Introduction and implementation of liquid biopsy: Dr. Daisy Escobar explains that liquid biopsy, or cell-free DNA (cfDNA) technology, involves a simple blood draw used primarily to monitor treatment response and detect relapse or recurrence in cancer patients. Unlike traditional biopsies that require tissue samples, liquid biopsy offers a less invasive alternative for surveillance. The ease of monitoring is particularly beneficial for cancer patients who are frequently undergoing lab tests for other reasons. Dr. Escobar details the conditional nature of liquid biopsy's current use, emphasizing its role in patient monitoring rather than initial cancer diagnosis.
2. Challenges and limitations: Despite its advantages, liquid biopsy is not without its challenges. Dr. Escobar mentions the necessity of comparing ctDNA with DNA from a previous biopsy. Additionally, certain conditions, such as a previous bone marrow transplant, may limit ctDNA effectiveness. Another significant challenge is the potential for emotional impact on patients due to "watchful worrying," knowing that while their markers may be rising, visible signs of cancer may not immediately appear on scans.
3. Potential and future of liquid biopsy: Dr. Escobar discusses the hopeful future of cfDNA technology, particularly for the early detection of ovarian and pancreatic cancers, which currently lack effective screening methods. Advancements in identifying specific ctDNA signatures for various cancers could revolutionize early detection and management, reducing the necessity for more invasive procedures. However, she underscores that while promising, the science has yet to fully catch up to the technology, and ongoing research is crucial.
In this episode, Dr. JYP welcomes medical oncologist and hematologist Dr. Daisy Escobar to discuss her background and her expertise in cancer diagnosis and treatment. Dr. Escobar shares her journey to the Mitchell Cancer Institute and talks about her family. The conversation focuses on cell-free DNA technology, also known as liquid biopsy, which is used primarily for cancer surveillance and monitoring. Dr. Escobar explains the benefits and limitations of this technology, including how it compares with traditional biopsies and its potential in early cancer detection. The conversation also covers the emotional aspects of cancer surveillance and the importance of patient autonomy in treatment decisions. Dr. Escobar emphasizes the importance of continual research and advancements in cancer diagnostics to improve patient outcomes.
3 Key Listener Takeaways 1. Introduction and implementation of liquid biopsy: Dr. Daisy Escobar explains that liquid biopsy, or cell-free DNA (cfDNA) technology, involves a simple blood draw used primarily to monitor treatment response and detect relapse or recurrence in cancer patients. Unlike traditional biopsies that require tissue samples, liquid biopsy offers a less invasive alternative for surveillance. The ease of monitoring is particularly beneficial for cancer patients who are frequently undergoing lab tests for other reasons. Dr. Escobar details the conditional nature of liquid biopsy's current use, emphasizing its role in patient monitoring rather than initial cancer diagnosis.
2. Challenges and limitations: Despite its advantages, liquid biopsy is not without its challenges. Dr. Escobar mentions the necessity of comparing ctDNA with DNA from a previous biopsy. Additionally, certain conditions, such as a previous bone marrow transplant, may limit ctDNA effectiveness. Another significant challenge is the potential for emotional impact on patients due to "watchful worrying," knowing that while their markers may be rising, visible signs of cancer may not immediately appear on scans.
3. Potential and future of liquid biopsy: Dr. Escobar discusses the hopeful future of cfDNA technology, particularly for the early detection of ovarian and pancreatic cancers, which currently lack effective screening methods. Advancements in identifying specific ctDNA signatures for various cancers could revolutionize early detection and management, reducing the necessity for more invasive procedures. However, she underscores that while promising, the science has yet to fully catch up to the technology, and ongoing research is crucial.
From the publisher's feed